11 November 2021 
EMA/CHMP/592765/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Vyepti 
eptinezumab 
On 11 November 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Vyepti, 
intended for the prophylaxis of migraine. 
The applicant for this medicinal product is H. Lundbeck A/S. 
Vyepti will be available as a 100 mg concentrate for solution for infusion. The active substance of Vyepti 
is eptinezumab, an analgesic (ATC code: N02CD05) that works by preventing the activation of the CGRP 
receptors.  
The benefit of Vyepti is a reduction in monthly migraine days. The most common side effects are 
nasopharyngitis and hypersensitivity.  
The full indication is: 
Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month. 
Vyepti should be prescribed by physicians experienced in the treatment of migraine. 
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
